NeuroSense Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.neurosense-tx.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06185543
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05436678
- Locations
- 🇺🇸
Novum, Las Vegas, Nevada, United States
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT05357950
- Locations
- 🇨🇦
Lawson Health Research Institute, London, Ontario, Canada
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇹IRCCS Istituti clinici Maugeri, Milano, Italy
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05232461
- Locations
- 🇺🇸
Novum, Fargo, North Dakota, United States
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Drug: Fixed dose combination Ciprofloxacin/Celecoxib
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04165850
- Locations
- 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
- Prev
- 1
- 2
- Next
News
NeuroSense to Present Promising Phase 2b Data for Novel ALS Drug PrimeC at AAN Meeting
NeuroSense Therapeutics will showcase new data from PrimeC's Phase 2b trial in ALS at the American Academy of Neurology Meeting on April 8, 2025, featuring presentations on clinical outcomes and microRNA biomarker findings.
NeuroSense Therapeutics Regains Nasdaq Compliance Amidst PrimeC Development for ALS
NeuroSense Therapeutics has regained compliance with Nasdaq's minimum equity requirement, ensuring its stock remains listed on the Nasdaq Capital Market.
NeuroSense Therapeutics Advances PrimeC for ALS with Global Pharma Partnership and FDA Guidance
NeuroSense Therapeutics has entered a binding term sheet with a leading global pharmaceutical company for PrimeC development, securing upfront payment and Phase 3 trial funding.
NeuroSense Therapeutics Presents PrimeC Data at ALS/MND Symposium
NeuroSense Therapeutics will present Phase 2b PARADIGM trial results of PrimeC, a potential ALS treatment, at the International Symposium on ALS/MND.
NeuroSense Therapeutics to Discuss Phase 3 Trial of PrimeC for ALS with FDA
NeuroSense Therapeutics will meet with the FDA to discuss the Phase 3 trial design for PrimeC, an experimental therapy for amyotrophic lateral sclerosis (ALS).
NeuroSense to Advance Phase 3 ALS Trial Following FDA Meeting
NeuroSense will meet with the FDA to finalize the Phase 3 trial design for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).
NeuroSense Advances ALS Program with FDA Meeting for PrimeC Phase 3 Trial
NeuroSense has scheduled a Type C meeting with the FDA on November 6, 2024, to finalize the Phase 3 trial design for PrimeC, a potential ALS treatment.
PrimeC Shows Significant Improvement in Key miRNAs for ALS Patients in PARADIGM Trial
NeuroSense Therapeutics' PrimeC demonstrated significant regulation of key microRNAs (miRNAs) in ALS patients, offering a potential disease-modifying treatment.
NeuroSense's PrimeC Demonstrates Efficacy in ALS, Pursues Early Approval in Canada
NeuroSense Therapeutics' PrimeC showed a 36% reduction in ALS disease progression and a 43% improvement in survival rates in clinical trials.
NeuroSense Therapeutics Regains Compliance with NASDAQ, Plans Phase 3 Trial for PrimeC
NeuroSense Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the exchange.